Mechelen, Belgium; 21 December 2011 - Galapagos NV (Euronext: GLPG)
announced
today that it has initiated clinical Phase I development of the first
inhibitor
of GPR43, a novel target for inflammatory diseases. This target was
identified
through Galapagos' proprietary target discovery platform.

GLPG0974 is an orally available small molecule that reduces migration
of
neutrophils, one of the critical cell types in inflammatory processes by
potent
inhibition of GPR43 (also known as FFAR2). Overactivity of neutrophils is
a
cause of tissue damage in illnesses such as inflammatory bowel disease, and
this
anti-inflammatory mechanism may provide for a novel treatment approach.
This
will be the first inhibitor of GPR43 to be evaluated clinically.

The First-in-Human study with GLPG0974 will focus on providing more
information
on its pharmacokinetics and pharmacodynamics, using an innovative design
for
clinical testing specifically intended for early clinical exploration of
novel
candidate drugs.

"GSK has decided to return the GPR43 program to Galapagos, and consequently
we
will not receive a milestone for initiation of this study," said Onno van
de
Stolpe, CEO of Galapagos. "We are encouraged by the results of this
program
thus far and have made the decision to continue moving forward with GLPG0974
on
our own."

Details of GLPG0974 First-in-Human trial

The primary endpoints of the first-in-human trial for GLPG0974 will be
to
determine the pharmacokinetics and to evaluate biomarker effects of
this
candidate drug. In addition, the safety and tolerability of a wide dose
range
will be evaluated. The placebo-controlled, double-blind, single ascending
dose
study is being conducted in 36 healthy human volunteers in Belgium over
the
coming months. It follows the design for exploratory single dose trials,
as
supported by guidelines that EMEA and the FDA designed to boost innovation
in
drug discovery and development.

About GLPG0974

GLPG0974 is an orally available small molecule, nanomolar inhibitor of GPR43
(G-protein coupled receptor), also known as FFAR2 (free fatty acid receptor
2),
which was identified by Galapagos as playing a key role in
inflammation.
GLPG0974 has shown potent inhibition of neutrophil migration (HOW)
and
successfully passed single dose animal safety evaluation. No other
inhibitors
of GPR43 are currently known to have been evaluated clinically.

About Galapagos

Galapagos (Euronext: GLPG) (PINKSHEETS: GLPYY) is a mid-size
biotechnology company
specialized in the discovery and development of small molecule and
antibody
therapies with novel modes-of-action. The Company is progressing GLPG0634,
as
well as one of the largest pipelines in biotech, with seven programs
in
development and over 50 discovery programs. The Galapagos Group has over
800
employees and operates facilities in six countries, with global headquarters
in
Mechelen, Belgium. More info at: www.glpg.com

This release may contain forward-looking statements, including,
without
limitation, statements containing the words "believes,"
"anticipates,"
"expects," "intends," "plans," "seeks," "estimates," "may," "will,"
"could,"
"stands to," and "continues," as well as similar expressions. Such
forward-looking statements may involve known and unknown risks, uncertainties
and other
factors which might cause the actual results, financial condition,
performance
or achievements of Galapagos, or industry results, to be materially
different
from any historic or future results, financial conditions, performance
or
achievements expressed or implied by such forward-looking statements.
Given
these uncertainties, the reader is advised not to place any undue reliance
on
such forward-looking statements. These forward-looking statements speak only
as
of the date of publication of this document. Galapagos expressly disclaims
any
obligation to update any such forward-looking statements in this document
to
reflect any change in its expectations with regard thereto or any change
in
events, conditions or circumstances on which any such statement is based,
unless
required by law or regulation.

This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:

(i) the releases contained herein are protected by copyright and
other applicable laws; and

(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.